Rhumbline Advisers Has $136,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Rhumbline Advisers grew its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 24.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,753 shares of the medical instruments supplier’s stock after purchasing an additional 9,512 shares during the quarter. Rhumbline Advisers’ holdings in Harvard Bioscience were worth $136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Assenagon Asset Management S.A. boosted its position in Harvard Bioscience by 193.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 227,701 shares of the medical instruments supplier’s stock valued at $649,000 after buying an additional 150,218 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Harvard Bioscience by 38.7% in the 1st quarter. BNP Paribas Financial Markets now owns 75,970 shares of the medical instruments supplier’s stock valued at $322,000 after purchasing an additional 21,183 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Harvard Bioscience by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock worth $783,000 after buying an additional 31,505 shares during the period. Vanguard Group Inc. raised its stake in shares of Harvard Bioscience by 2.4% during the first quarter. Vanguard Group Inc. now owns 2,152,147 shares of the medical instruments supplier’s stock worth $9,125,000 after buying an additional 49,576 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD bought a new position in Harvard Bioscience in the first quarter valued at approximately $54,000. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Trading Up 2.3 %

NASDAQ:HBIO opened at $2.72 on Monday. The stock has a market capitalization of $118.13 million, a PE ratio of -13.60 and a beta of 1.30. Harvard Bioscience, Inc. has a fifty-two week low of $2.50 and a fifty-two week high of $5.56. The business’s 50-day simple moving average is $2.92 and its 200-day simple moving average is $3.31. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). The business had revenue of $23.10 million for the quarter, compared to analyst estimates of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. Sell-side analysts expect that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current fiscal year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.